Nj\u00eb prov\u00eb klinike britanike nuk gjeti asnj\u00eb p\u00ebrfitim nga antivirali i Merck n\u00eb reduktimin e shtrimeve n\u00eb spital gjat\u00eb shp\u00ebrthimit t\u00eb Omicron. Nj\u00eb studim p\u00ebrkat\u00ebs i antiviralit t\u00eb Pfizer n\u00eb Izrael tregoi se ai ul rrezikun e vdekjes me 81% p\u00ebr ata mbi 65 vje\u00e7, por jo p\u00ebr t\u00eb rinjt\u00eb. Po ashtu \u00ebsht\u00eb ende duke u zbuluar pse shum\u00eb pacient\u00eb q\u00eb mor\u00ebn pilul\u00ebn Pfizer iu rikthyen kur e ndaluan marrjen e saj. Pilulat anti-covid jan\u00eb tashm\u00eb objekt studimi p\u00ebr efektet e tyre.<\/p>\n\n\n\n
Sa i p\u00ebrket studimit t\u00eb Merck’s Lagevrio, ai gjeti “asnj\u00eb ndryshim midis formulimit antiviral q\u00eb p\u00ebrmban Molnupiravir dhe nj\u00eb placebo n\u00eb reduktimin e shtrimeve n\u00eb spital p\u00ebr shkak t\u00eb Covid-19 gjat\u00eb val\u00ebs s\u00eb variantit Omicron. Pilula nuk \u00ebsht\u00eb treguar t\u00eb zvog\u00ebloj\u00eb rrezikun e shtrimit n\u00eb spital dhe vdekjes tek t\u00eb rriturit me rrezik t\u00eb lart\u00eb p\u00ebr s\u00ebmundje t\u00eb r\u00ebnda. “Rezultatet paraprake nga studimi i m\u00eb shum\u00eb se 25,000 njer\u00ebzve treguan se pilula mund t\u00eb zvog\u00ebloj\u00eb koh\u00ebn e rikuperimit t\u00eb pacient\u00ebve, por jo gjasat q\u00eb ata t\u00eb shtrohen n\u00eb spital.”<\/p>\n\n\n\n
Udh\u00ebheq\u00ebsi i studimit, profesor Chris Butler i Universitetit t\u00eb Oksfordit, sipas Financial Times, tha se nevojiteshin m\u00eb shum\u00eb analiza p\u00ebr t\u00eb lejuar autoritetet sh\u00ebndet\u00ebsore t\u00eb vendosin se si ta p\u00ebrdorin pilul\u00ebn m\u00eb pas. Shitjet e tij vler\u00ebsohen n\u00eb rreth 5 miliard\u00eb dollar\u00eb, por shum\u00eb ekspert\u00eb besojn\u00eb se ende nuk \u00ebsht\u00eb v\u00ebrtetuar se ofron p\u00ebrfitime t\u00eb prekshme p\u00ebr pacient\u00ebt.<\/p>\n\n\n\n
T\u00eb dh\u00ebnat fillestare nga nj\u00eb prov\u00eb e par\u00eb klinike n\u00eb 2021 kishin raportuar nj\u00eb reduktim af\u00ebrsisht 50% t\u00eb rrezikut t\u00eb shtrimit n\u00eb spital dhe vdekjes, por brenda disa muajsh kjo shif\u00ebr ishte ulur n\u00eb 30% nga k\u00ebrkimet m\u00eb t\u00eb reja. Tani duket se nuk ofron as 30%. Dr Andrew Hill i Universitetit t\u00eb Liverpulit tha: “N\u00ebse Molnupiravir nuk tregon asnj\u00eb p\u00ebrfitim, do t\u00eb jet\u00eb e v\u00ebshtir\u00eb p\u00ebr sh\u00ebrbimet sh\u00ebndet\u00ebsore t\u00eb justifikojn\u00eb 5.5 miliard\u00eb dollar\u00ebt e shpenzuar p\u00ebr k\u00ebt\u00eb ila\u00e7 n\u00eb mbar\u00eb bot\u00ebn. Ne kemi par\u00eb nj\u00eb situat\u00eb t\u00eb ngjashme n\u00eb t\u00eb kaluar\u00ebn me ila\u00e7e t\u00eb tjera Covid-19 si Remdesivir. Rezultatet fillestare duken inkurajuese, por provat klinike m\u00eb t\u00eb m\u00ebdha nuk kan\u00eb treguar asnj\u00eb p\u00ebrfitim.”<\/p>\n\n\n\n
Antiviral\u00ebt e tjer\u00eb<\/strong><\/p>\n\n\n\n Por sondazhet nuk jan\u00eb gjithmon\u00eb t\u00eb sigurta se pasqyrojn\u00eb realitetin. Vet\u00ebm pak muaj m\u00eb par\u00eb, nj\u00eb tjet\u00ebr studim tregoi se si pilulat Paxlovid t\u00eb Pfizer dhe Merck, si dhe nj\u00eb preparat i tret\u00eb me substanc\u00ebn fluvoxamine, kishin rezultate pozitive. Megjithat\u00eb, ve\u00e7an\u00ebrisht preparati i tret\u00eb nuk ishte aprovuar asnj\u00ebher\u00eb as nga Agjencia Amerikane e Barnave, e cila p\u00ebrgjith\u00ebsisht \u00ebsht\u00eb m\u00eb e \u201cleht\u00eb\u201d se ajo europiane n\u00eb p\u00ebrgatitjet e licencimit.<\/p>\n\n\n\n Zvog\u00eblohet “entuziazmi” p\u00ebr vaksinat e reja kund\u00ebr Covid 19<\/strong><\/p>\n\n\n\n Studimet n\u00eb Izrael treguan se nga ilaci p\u00ebrfitonte 81% p\u00ebr moshat mbi 65 vje\u00e7, por jo p\u00ebr ata m\u00eb t\u00eb rinj. Gjithashtu tregoi se shum\u00eb prej tyre shfaq\u00ebn simptoma sapo e ndaluan administrimin e tije, regjimi terapeutik i t\u00eb cilit \u00ebsht\u00eb pes\u00eb dit\u00eb. Studime t\u00eb tjera kan\u00eb treguar gjithashtu p\u00ebrfitime p\u00ebr ata m\u00eb t\u00eb rinj se 65 vje\u00e7, megjithat\u00eb, dhe p\u00ebrfundimet nuk jan\u00eb aq t\u00eb qarta sa do t\u00eb donim, pasi si t\u00eb gjitha barnat, Paxlovid ka kund\u00ebr indikacione dhe efekte an\u00ebsore, por \u00ebsht\u00eb nj\u00eb nga t\u00eb paktat e mbetura n\u00eb arsenal p\u00ebrtej vaksinimi.<\/p>\n\n\n\n P\u00ebr sa i p\u00ebrket faktit q\u00eb shum\u00eb pacient\u00eb q\u00eb kan\u00eb marr\u00eb pilul\u00ebn Pfizer \u201crikthehen\u201d disa dit\u00eb pas nd\u00ebrprerjes s\u00eb saj, nuk ka p\u00ebrfundime t\u00eb qarta. Nj\u00eb studim i vog\u00ebl i raportuar nga agjencia amerikane e lajmeve Reuters tregoi paradoksin se ata q\u00eb relapsuan kishin nj\u00eb nivel m\u00eb t\u00eb lart\u00eb t\u00eb antitrupave sesa ata q\u00eb nuk iu rikthyen. Gjithashtu, i nj\u00ebjti studim argumenton se p\u00ebrs\u00ebritja e simptomave nuk tregon se trajtimi nd\u00ebrhyri n\u00eb procesin natyral t\u00eb prodhimit t\u00eb antitrupave dhe e pengoi at\u00eb. Sipas Reuters, ata q\u00eb relapsuan kishin simptoma 80% m\u00eb t\u00eb buta se faza e par\u00eb e infeksionit dhe askush nuk kishte nevoj\u00eb p\u00ebr shtrimin n\u00eb spital. Megjithat\u00eb, ne nuk kemi t\u00eb dh\u00ebna se \u00e7far\u00eb \u00ebsht\u00eb e v\u00ebrtet\u00eb n\u00eb Evrop\u00eb, as nuk ka pasur nj\u00eb studim serioz nd\u00ebrkomb\u00ebtar me nj\u00eb num\u00ebr t\u00eb mjaftuesh\u00ebm pacient\u00ebsh q\u00eb kan\u00eb relapsuar pas nd\u00ebrprerjes s\u00eb mjekimit.<\/p>\n","protected":false},"excerpt":{"rendered":" Nj\u00eb prov\u00eb klinike britanike nuk gjeti asnj\u00eb p\u00ebrfitim nga antivirali i Merck n\u00eb reduktimin e shtrimeve n\u00eb spital gjat\u00eb shp\u00ebrthimit t\u00eb Omicron. Nj\u00eb studim p\u00ebrkat\u00ebs i antiviralit t\u00eb Pfizer n\u00eb Izrael tregoi se ai ul rrezikun e vdekjes me 81% p\u00ebr ata mbi 65 vje\u00e7, por jo p\u00ebr t\u00eb rinjt\u00eb. Po ashtu \u00ebsht\u00eb ende duke […]<\/p>\n","protected":false},"author":1,"featured_media":1855,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","footnotes":""},"categories":[281,279],"tags":[],"class_list":["post-5077","post","type-post","status-publish","format-standard","has-post-thumbnail","category-amerike","category-europe"],"yoast_head":"\n
Studimi izraelit q\u00eb n\u00eb t\u00eb v\u00ebrtet\u00eb mb\u00ebshtet Paxlovid \u00ebsht\u00eb nj\u00eb nga t\u00eb pakt\u00ebt q\u00eb \u00ebsht\u00eb b\u00ebr\u00eb n\u00eb praktik\u00eb dhe n\u00eb kushte reale spitalore gjat\u00eb val\u00ebs s\u00eb Omicron dhe n\u00ebn-varianteve t\u00eb tij. Ila\u00e7i kujtohet se \u00ebsht\u00eb testuar dhe miratuar “n\u00eb Delta” dhe jo “n\u00eb Omicron”. Ajo ishte testuar edhe n\u00eb pacient\u00eb t\u00eb pavaksinuar. K\u00ebshtu q\u00eb m\u00eb pas u ngrit\u00ebn pyetje se sa p\u00ebrfitonin nga mutacionet e tjera, si dhe t\u00eb vaksinuarit ose ata q\u00eb kishin imunitet natyror, sepse ata tashm\u00eb ishin prekur nga koronavirusi.<\/p>\n\n\n\n